Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
29 Sep 2025
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data.
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
28 Sep 2025
Romosozumab improves bone health in osteoporotic women with diabetes
Treatment with romosozumab for 12 months, followed by 24 months of alendronate, results in significant improvements in lumbar spine areal bone mineral density (BMD) and tissue thickness-adjusted trabecular bone score (TBS) algorithm (TBSTT) compared with alendronate alone among postmenopausal women with osteoporosis and type 2 diabetes (T2D), reports a study.